|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
|
JP6240600B2
(ja)
*
|
2011-07-24 |
2017-11-29 |
キュアテク リミテッド |
ヒト化免疫モノクローナル抗体の変異体
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
WO2014106104A1
(en)
*
|
2012-12-28 |
2014-07-03 |
Biogen Idec Ma Inc. |
Use of dr6 antagonists to improve motor neuron disease
|
|
US9580504B1
(en)
|
2013-11-07 |
2017-02-28 |
Curetech Ltd. |
Pidilizumab monoclonal antibody therapy following stem cell transplantation
|
|
CN105899539B
(zh)
|
2014-01-10 |
2021-11-09 |
博笛生物科技有限公司 |
用于免疫疗法的化合物和组合物
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
EP3114144A1
(en)
|
2014-03-05 |
2017-01-11 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
JP2017515859A
(ja)
|
2014-05-15 |
2017-06-15 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
EP3166976B2
(en)
|
2014-07-09 |
2026-04-08 |
Birdie Biopharmaceuticals Inc. |
Anti-pd-l1 combinations for treating tumors
|
|
US20170239351A1
(en)
|
2014-08-11 |
2017-08-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
|
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
|
EP3288982A1
(en)
|
2015-04-28 |
2018-03-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
|
|
US20160362489A1
(en)
|
2015-04-28 |
2016-12-15 |
Bristol-Myers Squibb Company |
Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
|
|
ES2739749T3
(es)
|
2015-05-18 |
2020-02-03 |
Tolero Pharmaceuticals Inc |
Profármacos de alvocidib que tienen biodisponibilidad aumentada
|
|
MA44594B1
(fr)
|
2015-05-29 |
2020-09-30 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
|
|
EP3302467A4
(en)
|
2015-05-31 |
2019-01-02 |
Curegenix Corporation |
Combination compositions for immunotherapy
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TWI870335B
(zh)
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
CN114591433A
(zh)
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
WO2017025498A1
(en)
|
2015-08-07 |
2017-02-16 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptide specific for lag-3 and pd-1
|
|
ES2980794T3
(es)
|
2015-09-15 |
2024-10-03 |
Acerta Pharma Bv |
Combinaciones terapéuticas de un inhibidor de CD19 y un inhibidor de BTK
|
|
EA201890790A1
(ru)
|
2015-09-29 |
2018-10-31 |
Селджин Корпорейшн |
Связывающие pd-1 белки и способы их применения
|
|
NZ739090A
(en)
|
2015-10-02 |
2025-06-27 |
Hoffmann La Roche |
Bispecific antibodies specific for pd1 and tim3
|
|
CN108136010A
(zh)
|
2015-10-08 |
2018-06-08 |
宏观基因有限公司 |
用于治疗癌症的联合疗法
|
|
AU2016350701B2
(en)
|
2015-11-02 |
2021-08-19 |
Five Prime Therapeutics, Inc. |
CD80 extracellular domain polypeptides and their use in cancer treatment
|
|
US20170145103A1
(en)
|
2015-11-23 |
2017-05-25 |
Five Prime Therapeutics, Inc. |
Predicting response to cancer treatment with fgfr2 inhibitors
|
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
JP7126941B2
(ja)
|
2015-12-22 |
2022-08-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
HUE052893T2
(hu)
|
2016-01-13 |
2021-05-28 |
Acerta Pharma Bv |
Antifolát és BTK-gátló terápiás kombinációi
|
|
JP2019511911A
(ja)
|
2016-02-17 |
2019-05-09 |
ノバルティス アーゲー |
Ｔｇｆベータ２抗体
|
|
TWI755395B
(zh)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
抗-pd-1抗體與輻射治療癌症之組合
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
JP7185530B2
(ja)
|
2016-06-13 |
2022-12-07 |
トルク セラピューティクス， インコーポレイテッド |
免疫細胞機能を促進するための方法および組成物
|
|
EP3500294A4
(en)
|
2016-08-22 |
2020-07-29 |
Arbutus Biopharma Corporation |
ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
|
|
CN110191720A
(zh)
|
2016-09-09 |
2019-08-30 |
Tg治疗有限公司 |
用于治疗血液学癌症的抗-CD20抗体、PI 3激酶-δ抑制剂以及抗-PD-1或抗-PD-L1抗体的组合
|
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
|
BR112019004733A2
(pt)
|
2016-09-19 |
2019-05-28 |
Celgene Corp |
métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
|
|
SG10201912663YA
(en)
|
2016-10-11 |
2020-03-30 |
Agenus Inc |
Anti-lag-3 antibodies and methods of use thereof
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
WO2018083087A2
(en)
|
2016-11-02 |
2018-05-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Binding proteins
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
WO2018106862A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
WO2018129533A1
(en)
|
2017-01-09 |
2018-07-12 |
Shuttle Pharmaceuticals, Llc |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
CN110198954A
(zh)
|
2017-01-13 |
2019-09-03 |
艾吉纳斯公司 |
与ny-eso-1结合的t细胞受体和其使用方法
|
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
|
US20200237874A1
(en)
|
2017-01-20 |
2020-07-30 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
DK3579874T3
(da)
|
2017-02-10 |
2021-10-11 |
Novartis Ag |
1-(4-amino-5-brom-6-(1h-pyrazol-1-yl)pyrimidin-2-yl)-1h-pyrazol-4-ol og anvendelse deraf til behandling af cancer
|
|
KR20240011262A
(ko)
|
2017-02-21 |
2024-01-25 |
리제너론 파아마슈티컬스, 인크. |
폐암의 치료를 위한 항-pd-1 항체
|
|
IL268836B2
(en)
|
2017-02-24 |
2024-04-01 |
Macrogenics Inc |
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
|
|
RU2761377C2
(ru)
|
2017-04-03 |
2021-12-07 |
Ф. Хоффманн-Ля Рош Аг |
Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
|
|
TWI690538B
(zh)
|
2017-04-05 |
2020-04-11 |
瑞士商赫孚孟拉羅股份公司 |
特異性結合至pd1至lag3的雙特異性抗體
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
JP7297672B2
(ja)
|
2017-04-13 |
2023-06-26 |
アジェナス インコーポレイテッド |
抗ｃｄ１３７抗体およびその使用方法
|
|
US12460208B2
(en)
|
2017-04-18 |
2025-11-04 |
Parr Biotechnology Co., Ltd. |
Immunomodulatory polynucleotides and uses thereof
|
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
|
CN118515666A
(zh)
|
2017-04-27 |
2024-08-20 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
WO2018201014A1
(en)
|
2017-04-28 |
2018-11-01 |
Five Prime Therapeutics, Inc. |
Methods of treatment with cd80 extracellular domain polypeptides
|
|
RS64576B1
(sr)
|
2017-05-01 |
2023-10-31 |
Agenus Inc |
Anti-tigit antitela i postupci njihove primene
|
|
CN110869392A
(zh)
|
2017-05-16 |
2020-03-06 |
百时美施贵宝公司 |
用抗gitr激动性抗体治疗癌症
|
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
|
EP3630179A2
(en)
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
|
SMT202300418T1
(it)
|
2017-05-30 |
2024-01-10 |
Bristol Myers Squibb Co |
Trattamento di tumori positivi per lag-3
|
|
AU2018277241B2
(en)
|
2017-05-31 |
2021-03-04 |
Novartis Ag |
Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1- yl)pyrimidin-4-amine and new salts
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
CN118307674A
(zh)
|
2017-06-22 |
2024-07-09 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
IL312120B2
(en)
|
2017-06-23 |
2025-06-01 |
Birdie Biopharmaceuticals Inc |
Pharmaceutical compositions
|
|
AU2018292618A1
(en)
|
2017-06-27 |
2019-12-19 |
Novartis Ag |
Dosage regimens for anti-TIM-3 antibodies and uses thereof
|
|
CN111163798A
(zh)
|
2017-07-20 |
2020-05-15 |
诺华股份有限公司 |
用于抗lag-3抗体的给药方案及其用途
|
|
KR20200052327A
(ko)
|
2017-09-04 |
2020-05-14 |
아게누스 인코포레이티드 |
혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법
|
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
|
TW201922291A
(zh)
|
2017-11-16 |
2019-06-16 |
瑞士商諾華公司 |
組合療法
|
|
BR112020010579A2
(pt)
|
2017-11-30 |
2020-11-10 |
Novartis Ag |
receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
US11407723B2
(en)
|
2018-01-09 |
2022-08-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
WO2019140150A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
CA3096287A1
(en)
|
2018-01-22 |
2019-07-25 |
Pascal Biosciences Inc. |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
|
US20200354457A1
(en)
|
2018-01-31 |
2020-11-12 |
Hoffmann-La Roche Inc. |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
US20210147570A1
(en)
|
2018-04-12 |
2021-05-20 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
MA52363A
(fr)
|
2018-04-26 |
2021-03-03 |
Agenus Inc |
Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
|
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
|
TW202504917A
(zh)
|
2018-06-21 |
2025-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
|
MX2021000726A
(es)
|
2018-07-26 |
2021-03-25 |
Bristol Myers Squibb Co |
Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer.
|
|
CN112955221A
(zh)
|
2018-08-27 |
2021-06-11 |
皮里斯制药有限公司 |
包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
|
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
|
CA3112599A1
(en)
|
2018-09-20 |
2020-03-26 |
Iovance Biotherapeutics, Inc. |
Expansion of tils from cryopreserved tumor samples
|
|
KR102262012B1
(ko)
|
2018-10-15 |
2021-06-09 |
연세대학교 산학협력단 |
생산성이 향상된 항체 및 이의 제조방법
|
|
US20210348238A1
(en)
|
2018-10-16 |
2021-11-11 |
Novartis Ag |
Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
|
|
HUE067601T2
(hu)
|
2018-11-14 |
2024-10-28 |
Regeneron Pharma |
PD-1 inhibitorok intraléziós beadása a bõrrák kezelésére
|
|
US11034710B2
(en)
|
2018-12-04 |
2021-06-15 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
NZ778055A
(en)
|
2019-02-12 |
2025-11-28 |
Sumitomo Pharma America Inc |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
MX2021009562A
(es)
|
2019-02-12 |
2021-09-08 |
Novartis Ag |
Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
|
|
MA55084A
(fr)
|
2019-02-28 |
2022-01-05 |
Regeneron Pharma |
Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
|
|
MA55204A
(fr)
|
2019-03-06 |
2022-01-12 |
Regeneron Pharma |
Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
CA3133460A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
SG11202111262XA
(en)
|
2019-05-13 |
2021-11-29 |
Regeneron Pharma |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
|
|
JP2022536850A
(ja)
|
2019-06-18 |
2022-08-19 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
|
|
MA56533A
(fr)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Co |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1
|
|
JP2022539208A
(ja)
|
2019-07-03 |
2022-09-07 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
|
|
GB201912107D0
(en)
|
2019-08-22 |
2019-10-09 |
Amazentis Sa |
Combination
|
|
TW202122420A
(zh)
|
2019-08-30 |
2021-06-16 |
美商艾吉納斯公司 |
抗ｃｄ９６抗體及其使用方法
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
TW202128191A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
Tim-3抑制劑及其用途
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
|
WO2021102343A1
(en)
|
2019-11-22 |
2021-05-27 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
JP2023510393A
(ja)
|
2020-01-17 |
2023-03-13 |
ノバルティス アーゲー |
骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ
|
|
KR20220132598A
(ko)
|
2020-01-28 |
2022-09-30 |
제넨테크, 인크. |
암 치료를 위한 IL15/IL15R 알파 이종이량체 Fc-융합 단백질
|
|
EP4110341A2
(en)
|
2020-02-28 |
2023-01-04 |
Novartis AG |
A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor
|
|
JP2023523193A
(ja)
|
2020-04-21 |
2023-06-02 |
ノバルティス アーゲー |
Ｃｓｆ－１ｒにより調節される疾患を治療するための投与レジメン
|
|
US12159700B2
(en)
|
2020-04-22 |
2024-12-03 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
MX2022014734A
(es)
|
2020-05-26 |
2023-03-15 |
Regeneron Pharma |
Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab.
|
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
|
JP2023540217A
(ja)
|
2020-08-26 |
2023-09-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｐｄ－１阻害剤を投与することによりがんを処置する方法
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
JP2023542490A
(ja)
|
2020-09-03 |
2023-10-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｐｄ－１阻害剤を投与することによりがん疼痛を処置する方法
|
|
US20230374160A1
(en)
|
2020-10-02 |
2023-11-23 |
Regeneron Pharmaceuticals, Inc. |
Combination of antibodies for treating cancer with reduced cytokine release syndrome
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022087402A1
(en)
|
2020-10-23 |
2022-04-28 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
|
EP4313123A1
(en)
|
2021-03-23 |
2024-02-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
|
|
AU2022246174A1
(en)
|
2021-03-25 |
2023-09-14 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
EP4323356A1
(en)
|
2021-04-13 |
2024-02-21 |
Nuvalent, Inc. |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
WO2022247972A2
(es)
|
2021-05-26 |
2022-12-01 |
Centro De Inmunologia Molecular |
Uso de composiciones terapéuticas para el tratamiento de pacientes con tumores de origen epitelial
|
|
MX2024000406A
(es)
|
2021-07-19 |
2024-04-18 |
Regeneron Pharma |
Combinacion de inhibidores de puntos de control y un virus oncolitico para el tratamiento del cancer.
|
|
WO2023015198A1
(en)
|
2021-08-04 |
2023-02-09 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
|
|
KR20240130137A
(ko)
|
2022-01-07 |
2024-08-28 |
리제너론 파아마슈티컬스, 인크. |
이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와의 조합으로 재발성 난소암을 치료하는 방법
|
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
US20250152643A1
(en)
|
2022-02-17 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
|
|
US20230277669A1
(en)
|
2022-02-24 |
2023-09-07 |
Amazentis Sa |
Uses of urolithins
|
|
KR20240159849A
(ko)
|
2022-03-17 |
2024-11-06 |
리제너론 파아마슈티컬스, 인크. |
이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와 병용으로 재발성 상피 육종을 치료하는 방법
|
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
CA3248034A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
|
|
KR20250010677A
(ko)
|
2022-05-16 |
2025-01-21 |
리제너론 파아마슈티컬스, 인크. |
이중특이적 항-PSMA x 항-CD3 항체를 단독으로 또는 항-PD-1 항체와 병용으로 전이성 거세 저항성 전립선암을 치료하는 방법
|
|
KR20250044313A
(ko)
|
2022-07-27 |
2025-03-31 |
아스트라제네카 아베 |
Pd-1/pd-l1 저해제와 인터루킨-12를 발현하는 재조합 바이러스의 조합물
|
|
IL318426A
(en)
|
2022-08-02 |
2025-03-01 |
Regeneron Pharma |
Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28 in combination with anti-PD-1 antibodies
|
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
|
KR20250099774A
(ko)
|
2022-10-03 |
2025-07-02 |
리제너론 파아마슈티컬스, 인크. |
이중특이적 egfr x cd28 항체를 단독으로 또는 항-pd-1 항체와 조합하여 사용하여 암을 치료하는 방법
|
|
EP4623072A2
(en)
|
2022-11-21 |
2025-10-01 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
EP4626552A1
(en)
|
2022-12-01 |
2025-10-08 |
MedImmune Limited |
Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
|
|
WO2024150177A1
(en)
|
2023-01-11 |
2024-07-18 |
Advesya |
Treatment methods for solid tumors
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
WO2024192033A1
(en)
|
2023-03-13 |
2024-09-19 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
EP4701650A2
(en)
|
2023-04-26 |
2026-03-04 |
Isabella Pharma B.V. |
Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
|
|
CN121620536A
(zh)
|
2023-08-02 |
2026-03-06 |
瑞泽恩制药公司 |
用双特异性抗PSMAx抗CD28抗体治疗透明细胞肾细胞癌的方法
|
|
WO2025030041A1
(en)
|
2023-08-02 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies
|
|
WO2025051895A1
(en)
|
2023-09-06 |
2025-03-13 |
Novimmune Sa |
Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
|
|
US20250114468A1
(en)
|
2023-10-09 |
2025-04-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
|
|
WO2025106736A2
(en)
|
2023-11-15 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
|
|
TW202539732A
(zh)
|
2023-11-29 |
2025-10-16 |
美商再生元醫藥公司 |
以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法
|
|
TW202542187A
(zh)
|
2023-12-12 |
2025-11-01 |
美商再生元醫藥公司 |
以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|
|
WO2026015612A1
(en)
|
2024-07-10 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating smarcb1-deficient cancers
|
|
WO2026035866A1
(en)
|
2024-08-07 |
2026-02-12 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor
|
|
WO2026059920A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors
|